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Summary
Background:  It  has  been  reported  that  patients  with  obstructive  sleep  apnea  (OSA)  have  an
elevated arterial  stiffness,  and  alleviation  of  OSA  by  continuous  positive  airway  pressure  (CPAP)
might attenuate  this.  Recently,  the  cardio-ankle  vascular  index  (CAVI)  has  been  reported  to  be
a highly  reproducible  arterial  stiffness  parameter  in  OSA  patients.  However,  the  change  in  CAVI
that occurs  following  long-term  CPAP  treatment  for  OSA  remains  unclear.
Methods:  Patients  with  moderate-to-severe  OSA  were  enrolled.  Changes  in  CAVI  at  1  and  12
months after  CPAP  initiation  (CAVI1 and  CAVI12,  respectively)  were  assessed.  Factors  associ-
ated with  CAVI1 and  CAVI12 were  determined  by  multivariable  regression  analyses.
Results: Thirty  subjects  were  assessed.  CAVI  was  signiﬁcantly  reduced  at  1  month  compared
with the  baseline  from  7.80  ±  1.19  to  7.56  ±  1.08  (p  =  0.013).  A  non-signiﬁcant  reduction  was
observed at  12  months  (7.72  ±  1.18,  p  =  0.365  versus  baseline)  and  CAVI  had  actually  increased
compared  with  that  measured  at  1  month.  In  multivariable  analyses,  CAVI1 was  inversely
correlated  with  CPAP  usage  (coefﬁcient:  −0.500,  p  =  0.006)  and  was  directly  correlated  with
the change  in  the  ratio  of  low  frequency  to  high  frequency  in  heart  rate  variability  (coefﬁcient:
0.607, p  <  0.001),  whereas  CAVI12 was  related  to  the  use  of  angiotensin-converting  enzyme
inhibitors (ACE-I)  or  angiotensin-II-receptor  blockers  (ARB;  coefﬁcient:  0.464,  p  =  0.013),  was
directly correlated  with  the  change  in  hemoglobin  A1c  levels  (coefﬁcient:  0.644,  p  <  0.001),  and
was inversely  correlated  with  the  change  in  CPAP  usage  (coefﬁcient:  −0.380,  p  =  0.046).
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Conclusions:  CAVI  was  signiﬁcantly  reduced  by  short-term  CPAP  and  then  slightly  increased  from
1 to  12  months,  which  was  probably  due  to  natural  progression  associated  with  the  aging  process.
However, long-term  CPAP  treatment  had  the  beneﬁcial  effect  of  maintaining  CAVI  below  baseline
levels when  associated  with  the  use  of  ACE-I/ARB,  the  control  of  blood  glucose  and  the  CPAP
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using  a  latex  particle-enhanced  turbidimetric  immunoassay.
Serum  total  and  high-density  lipoprotein  (HDL)  cholesterol,
triglycerides,  creatinine,  and  glycosylated  hemoglobincompliance.
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Introduction
Obstructive  sleep  apnea  (OSA)  is  a  common  disorder  [1]  that
is  associated  with  increased  cardiovascular  morbidity  and
mortality  [2—8]. Independent  from  comorbidities  including
obesity  [9],  hypertension  [10], and  dysglycemia  [11], all  of
which  are  also  well-established  cardiovascular  risk  factors,
OSA  per  se  may  play  a  role  in  the  development  of  cardio-
vascular  diseases  through  structural  and  functional  vascular
damage  by  sympathetic  overactivation  [12], inﬂammation
[13], and  increased  production  of  reactive  oxygen  species
[14].  In  fact,  several  indicators  of  vascular  damage,  includ-
ing  arterial  stiffness,  have  been  shown  to  be  related  to
the  severity  of  OSA  [15—18]. In  contrast,  it  has  also  been
reported  that  the  alleviation  of  OSA  by  continuous  posi-
tive  airway  pressure  (CPAP)  might  attenuate  such  elevated
arterial  stiffness  [19—24].
Recently,  a  new  arterial  stiffness  parameter,  the  cardio-
ankle  vascular  index  (CAVI),  was  developed  based  on  pulse
wave  velocity  (PWV)  and  stiffness  parameter  ˇ  [25,26].  CAVI
is  believed  to  be  little  affected  by  blood  pressure  at  the
time  of  measurement.  Furthermore,  it  has  been  shown  to
be  compatible  with  carotid-femoral  (cf)  PWV  [25]  and  has
been  recently  reported  to  be  a  highly  reproducible  arterial
stiffness  parameter  in  OSA  patients  [27]. In  addition,  it  has
been  reported  that  patients  with  more  severe  OSA  had  a
greater  CAVI  value,  indicating  that  their  vascular  function
was  more  damaged  [27]. More  recently,  a  reduction  in  CAVI
has  been  observed  1  month  after  the  initiation  of  effective
CPAP  treatment  in  association  with  CPAP  compliance  [28].
However,  the  long-term  efﬁcacy  of  CPAP  treatment  for  OSA
on  CAVI  remains  unclear.
The  aims  of  the  present  study  were  as  follows:  (1)
to  investigate  the  change  in  CAVI  following  short-term  (1
month)  and  long-term  (12  months)  CPAP  treatment  for  OSA;
and  (2)  to  determine  the  factors  that  affect  the  change  in
CAVI.
Methods
Subjects
Thirty-seven  patients  were  recruited  from  the  population  of
OSA  patients  who  were  enrolled  in  our  previous  study  [27],
where  the  validity  of  the  CAVI  measurement  among  patients
with  OSA  was  investigated.  Details  of  our  previous  study
are  described  elsewhere  [27]. In  brief,  that  study  included
adults  (age  ≥20  years)  and  patients  with  OSA,  which  was
deﬁned  as  an  apnea—hypopnea  index  (AHI)  ≥5  events  per
hour  of  sleep.  Patients  with  heart  failure,  patients  with
cerebrovascular  disease  with  a  neurological  deﬁcit,  patients
with  aortic  disease,  patients  with  peripheral  vascular  dis-
ease,  patients  on  dialysis,  patients  whose  electrocardiogram
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evealed  atrial  ﬁbrillation  or  frequent  episodes  of  atrial
nd  ventricular  ectopies,  and  patients  whose  ankle-brachial
ndex  was  less  than  0.9  at  the  time  of  CAVI  measurement
ere  excluded.  For  the  current  study,  we  enrolled  patients
ho  had  moderate  to  severe  OSA,  which  was  deﬁned  as  AHI
15  per  hour  of  sleep,  who  were  stable  medically  without
edication  changes  for  ≥6  months,  and  who  agreed  with
he  long-term  follow-up  protocol.  There  were  no  overlaps
n  the  enrolled  subjects  between  the  present  study  and
ur  previous  study  in  which  the  relationship  between  cir-
ulating  inﬂammatory  markers  and  CAVI  in  men  with  OSA
nd  the  efﬁcacy  of  CPAP  therapy  were  assessed  [28]. The
oranomon  Hospital  Ethics  Committee  approved  the  study,
nd  informed  consent  to  participate  was  obtained  from  all
ubjects.
leep  studies  and  CPAP  treatment
ll  subjects  underwent  overnight  polysomnography  using
 digital  polygraph  (SomnoStar  Alpha  Sleep  System,  Sen-
orMedics  Corp.,  Yorba  Linda,  CA,  USA)  at  our  laboratory
Sleep  Center,  Toranomon  Hospital,  Tokyo,  Japan)  and
he  previously  described  deﬁnitions  and  scoring  meth-
ds  were  used  [29]. Patients  who  were  diagnosed  with
oderate  to  severe  OSA  were  counseled  and  initiated
nto  CPAP  treatment  after  manual  ascertainment  of  the
ppropriate  pressure  setting  on  a  second  (CPAP  titration)
tudy.
easurement  of  CAVI
AVI  was  measured  using  a Vasera  VS-1000  device  (Fukuda
enshi,  Tokyo,  Japan)  while  the  subjects  were  awake
etween  8:00  AM  and  12:00  noon,  and  on  the  same  day,
lood  pressure  (BP)  data,  anthropometric  data,  and  blood
amples  were  collected.  CAVI  reﬂects  the  stiffness  of  the
orta,  femoral  arteries,  and  tibial  arteries  as  a  whole
25,27].
lood  samples  and  other  data  collected
enous  blood  samples  that  were  obtained  during  the
orning  (7:00—8:00  AM)  after  an  overnight  fast  were  sep-
rated  by  centrifugation  and  stored  at  −80 ◦C.  Serum
-reactive  protein  (CRP)  concentration  was  measuredhemoglobin  A1c  (HbA1c)]  were  measured  using  an  auto-
atic  analyzer.  BP  and  heart  rate  were  measured  on  the
ame  day  as  the  CAVI  measurement.  BP  was  measured  using
 sphygmomanometer  with  an  appropriately  sized  cuff  while
7 M.  Kato  et  al.
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Table  1  Characteristics  of  patients.
N  =  30
Age  (years)  57.2  ±  11.0
Male  gender,  n  (%)  28  (93.3)
Smokers,  n  (%)  14  (46.7)
Hypertension,  n  (%)  15  (50.0)
Diabetes  mellitus,  n  (%)  3  (10.0)
ESS 10.5  ±  3.7
Medication
Statin,  n  (%) 7  (23.3)
ACE-I/ARB,  n  (%) 10  (33.3)
CCB, n  (%) 10  (33.3)
Beta blocker,  n  (%)  7  (23.3)
Anti-diabetes,  n  (%)  2  (6.7)
ESS, Epworth sleepiness scale; ACE-I, angiotensin-converting
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atients  were  seated  after  5  min  of  rest.  Three  consecu-
ive  measurements  were  carried  out  and  the  mean  of  the
ast  two  BP  values  was  recorded.  Height  and  weight  were
lso  measured  at  the  same  time.  Electrocardiogram  was
ecorded  for  15  min  when  the  subjects  were  in  a  supine  posi-
ion  just  after  awakening  in  the  morning  of  both  diagnostic
leep  study  and  CPAP  titration,  and  the  heart  rate  variabil-
ty  (HRV)  was  determined.  HRV  was  analyzed  by  using  the
ommercially  available  software  for  frequency  domain  anal-
sis  of  HRV  (R-R  Interval  Analysis,  NoruPro  Light  Systems,
okyo,  Japan),  which  estimates  the  spectra  using  the  Mem-
alc  method;  further,  low-frequency  (LF;  0.04—0.150  Hz),
igh-frequency  (HF;  0.150—0.400  Hz),  and  LF  to  HF  power
LF/HF)  ratio  were  calculated.  The  Epworth  sleepiness
cale  (ESS)  score  was  computed  to  assess  subjective
leepiness  [30].
ollow-up  protocol
fter  1  and  12  months  of  CPAP  treatment,  fasting  blood
ampling  and  CAVI  measurements  were  repeated  along  with
easurements  of  BP,  heart  rate,  and  weight.  During  the
ollow-up  period,  an  objective  evaluation  of  compliance
as  carried  out  by  downloading  data  stored  in  the  CPAP
evices.
tatistical analysis
ata  are  expressed  as  the  mean  ±  SD  for  continuous  vari-
bles,  or  as  numbers  and  percentages  for  categorical
ariables.  Sleep  study  parameters  during  the  diagnostic  and
he  CPAP  titration  studies,  HRV  parameters,  CPAP  levels,
nd  usage  were  compared  using  a  paired  Student’s  t-test
r  a  Wilcoxon  signed-rank  test,  as  appropriate.  Changes  in
arameters,  including  CAVI,  BP,  heart  rate,  body  mass  index
BMI),  total  and  HDL  cholesterol,  triglycerides,  HbA1c,  crea-
inine,  and  CRP,  were  compared  using  a  repeated-measures
nalysis  of  variance  with  Bonferroni  correction.  In  order
o  identify  the  factors  that  were  correlated  with  change
n  CAVI  at  1  month  or  12  months  (CAVI1 and  CAVI12,
espectively),  we  performed  univariate  regression  analy-
is  by  using  the  following  independent  variables:  baseline
ariables  (age,  gender,  BMI,  smoking  status,  hypertension,
iabetes  mellitus,  use  of  medication,  ESS,  BP,  heart  rate,
nd  data  from  the  blood  test);  diagnostic  sleep  study  param-
ters  [AHI,  arousal  index,  lowest  SO2,  %  of  slow  wave  sleep
SWS)  and  rapid  eye  movement  (REM)  sleep];  HRV  parame-
ers  after  diagnostic  sleep  study  (LF,  HF,  and  LF/HF);  changes
n  the  sleep  study  parameters  at  CPAP  titration  (AHI,
arousal  index,  lowest  SO2,  %  of  SWS,  and  %  of  REM
leep);  changes  in  the  HRV  parameters  on  the  morning  of
PAP  titration  (LF,  HF,  and  LF/HF);  changes  in  BMI,
P,  heart  rate,  blood  test  data  (changes  during  1  month
ere  used  for  the  analysis  of  CAVI1 and  changes  during
he  12  months  were  used  for  the  analysis  of  CAVI12),  the
ean  night  CPAP  usage  during  initial  1  month  and  applied
PAP  level  during  the  initial  1  month  for  CAVI1 analysis,
nd  change  in  the  mean  night  CPAP  usage  and  applied  CPAP
evel  from  the  1st  month  and  the  last  month  for  CAVI12
nalysis.  The  variables  that  showed  a  relationship  with
CAVI1 or  CAVI12 with  p  <  0.1  were  included  in  each  mul-
t
a
r
aenzyme inhibitors; ARB, angiotensin receptor blockers; CCB, cal-
cium channel blocker.
ivariate  analysis.  We  ﬁnally  developed  multivariate  models
sing  the  variables  selected  from  the  univariate  analy-
is,  followed  by  stepwise  model  selection  with  p  <  0.05  for
nclusion  and  p  >  0.1  for  removal.  Statistical  analyses  were
erformed  using  SPSS  ver.  11  (SPSS  Inc.,  Chicago,  IL,  USA),
nd  a  p-value  less  than  0.05  was  considered  statistically
igniﬁcant.
esults
haracteristics  of  the  subjects
ut  of  the  37  patients,  one  subject  declined  to  use  the
PAP  just  after  the  CPAP  titration,  three  withdrew  their  con-
ent  for  personal  reasons,  and  three  stopped  using  the  CPAP
fter  1  month.  Therefore,  30  patients  were  able  to  complete
he  study.  The  clinical  characteristics  of  these  patients  are
hown  in  Table  1.  Most  of  the  patients  were  middle-aged  men
nd  half  of  them  had  a  history  of  hypertension.  Of  these,  10
atients  were  treated  with  angiotensin-converting  enzyme
nhibitors  (ACE-I)  or  angiotensin  II  receptor  blockers  (ARB),
0  were  taking  calcium-channel  blockers,  and  7  were  taking
eta  blockers.  Three  patients  had  a  history  of  diabetes  mel-
itus,  and  two  of  these  were  being  treated  with  anti-diabetes
edication.
iagnostic  sleep  study  and  CPAP  titration
he  data  from  the  two  sleep  studies  are  shown  in  Table  2.
ost  of  the  subjects  had  severe  OSA  with  nocturnal  hypoxia
nd  poor  sleep  quality  in  the  diagnostic  study.  However,
e  conﬁrmed  improvement  of  almost  all  parameters  on
PAP  in  the  CPAP  titration  study.  CPAP  during  the  initial
onth  was  6.9  ±  1.8  cm  H2O  and  that  during  the  last  month
as  6.6  ±  1.7  cm  H2O  (p  =  0.020).  Night  CPAP  usage  during  1
onth  and  after  12  months  was  4.9  ±  1.4  and  4.6  ±  1.9  h  per
ight,  respectively  (p  =  0.393).  In  the  HRV  analyses,  LF  in
he  morning  after  diagnostic  sleep  study  and  in  the  morning
fter  CPAP  titration  study  were  528  ±  461  and  418  ±  474  ms2,
espectively  (p  =  0.229),  and  HF  after  diagnostic  study  and
fter  titration  study  were  148  ±  154  and  208  ±  269  ms2,
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Table  2  Diagnostic  sleep  study  and  CPAP  titration  ﬁndings.
Diagnostic  study  CPAP  titration  p
Total  sleep  time  (min)  358.6  ±  64.3  386.1  ±  49.0  0.061
AHI (events/h)  37.6  ±  21.7  3.2  ±  3.7  <0.001
Mean SO2 (%)  96.0  ±  1.6  96.8  ±  1.0  0.006
Lowest SO2 (%)  79.3  ±  6.7  89.5  ±  4.8  <0.001
SO2 <  90%  (%TST)  18.6  ±  25.3  0.8  ±  1.9  <0.001
Arousal index  (events/h) 40.7  ±  20.9  16.6  ±  9.1  <0.001
Slow wave  sleep  (%TST) 5.3 ±  6.2  11.7  ±  6.6  <0.001
REM sleep  (%TST) 10.4 ±  5.4  17.0 ±  5.2  <0.001
Data are presented as the mean ± SD. CPAP, continuous positive airw
saturation; TST, total sleep time; REM, rapid eye movement.
respectively  (p  =  0.371).  LF/HF  in  the  morning  after  titration
study  was  signiﬁcantly  lower  than  that  after  diagnostic  study
(4.9  ±  3.5,  LF/HF  after  diagnostic  study;  3.2  ±  3.2,  LF/HF
after  titration  study;  p  =  0.009).
Changes  in  CAVI  and  other  parameters  after  CPAP
therapy
Change  in  CAVI  during  the  follow-up  period  is  shown  in
Fig.  1.  From  baseline  to  1  month  after  the  initiation  of
CPAP,  CAVI  decreased  signiﬁcantly.  However,  after  1  month,
CAVI  increased  slightly  to  12  months,  but  at  12  months
CAVI  still  remained  below  the  baseline  level.  The  changes
in  other  parameters  are  shown  in  Table  3.  Even  though
BMI  did  not  change  over  the  follow-up  period,  HbA1c  levels
decreased,  especially  from  baseline  to  1  month,  and  then
Figure  1  The  change  in  CAVI  from  baseline  to  1  month,  and  to
12 months  after  CPAP  initiation.  CAVI  was  signiﬁcantly  reduced
at 1  month  from  7.80  ±  1.19  to  7.56  ±  1.08  (p  =  0.013),  but
increased  gradually  thereafter.  Although  there  was  no  signif-
icant  difference  between  baseline  and  12  months  (p  =  0.365),
CAVI at  12  months  (7.72  ±  1.18)  remained  below  the  baseline
value.  CAVI,  cardio-ankle  vascular  index;  CPAP,  continuous  pos-
itive airway  pressure.
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lightly  increased  from  1  month  to  12  months.  In  addition,
DL  cholesterol  levels  increased  at  12  months  compared  to
aseline.
actors  related  to  the  CAVI1 and  CAVI12
n  the  univariate  analysis  for  CAVI1,  we  found  that  base-
ine  ESS  score,  systolic  BP  level,  and  the  percentage  of  REM
leep  during  the  diagnostic  sleep  study  had  a  tendency  to  be
nversely  correlated  with  CAVI1 (Table  4).  In  addition,  the
hanges  in  the  lowest  SO2 level  from  the  diagnostic  sleep
tudy  to  the  CPAP  titration  and  night  CPAP  usage  during
he  initial  1  month  were  inversely  correlated  with  CAVI1
Table  5).  The  changes  in  LF  and  LF/HF  (LF/HF)  from  the
iagnostic  sleep  study  to  the  CPAP  titration  were  directly
orrelated  with  CAVI1 (Table  5).  Further,  change  in  HDL  lev-
ls  (HDL)  and  change  in  HF  from  the  diagnostic  sleep  study
o  the  CPAP  titration  had  a  tendency  to  be  inversely  corre-
ated  with  CAVI1 (Table  5).  All  of  these  variables  were  then
ncluded  in  a  stepwise  multivariate  analysis,  which  showed
hat  night  CPAP  usage  during  the  initial  1  month  (partial  cor-
elation  coefﬁcient,  −0.500;  p  =  0.006)  and  LF/HF  (partial
orrelation  coefﬁcient,  0.607;  p  <  0.001)  were  the  only  inde-
endent  variables  that  were  signiﬁcantly  correlated  with
CAVI1,  and  these  variables  accounted  for  54%  of  variability
r  =  0.734,  p  =  0.006  for  the  total  model).
In  the  univariate  analysis  for  CAVI12,  we  found  that  the
se  of  calcium-channel  blockers  was  signiﬁcantly  related  to
CAVI12, and  that  the  presence  or  absence  of  hypertension
nd  the  use  of  ACE-I/ARB  had  a  tendency  to  be  related  to
CAVI12 (Table  4).  The  change  in  diastolic  BP  and  the  change
n  HbA1c  levels  (HbA1c)  were  positively  correlated  with
CAVI12 (Table  5).  The  change  in  night  CPAP  usage  from  the
nitial  1  month  to  the  last  1  month  (CPAP  usage)  and  HDL
ere  inversely  correlated  with  CAVI12 (Table  5).  The  pres-
nce  or  absence  of  hypertension  was  not  included  in  the
ultivariate  analysis  because  of  an  issue  with  colinearity.
ll  of  these  variables,  except  the  presence  or  absence  of
ypertension,  were  then  included  in  a  stepwise  multivariate
nalysis,  which  showed  that  the  use  of  ACE-I/ARB  (par-
ial  correlation  coefﬁcient,  0.464;  p  =  0.013),  HbA1c  levels
partial  correlation  coefﬁcient,  0.505;  p  =  0.006),  and  CPAP
sage  (partial  correlation  coefﬁcient,  −0.380;  p  =  0.046)
ccounted  for  55%  of  the  variability  (r  =  0.744,  p  =  0.046  for
he  total  model).
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Table  3  Changes  in  clinical  parameters  other  than  CAVI.
Baseline  1  month  p* 12  months  p† p‡
BMI  (kg/m2)  27.3  ±  4.6  27.3  ±  4.8  1.000  27.1  ±  4.7  0.483  0.129
Systolic BP  (mm  Hg)  132.5  ±  17.1  129.1  ±  15.1  0.510  132.7  ±  16.3  1.000  0.325
Diastolic BP  (mm  Hg)  84.1  ±  9.3  82.6  ±  9.1  0.959  86.3  ±  9.8  0.627  0.088
Heart rate  (min−1)  66.4  ±  12.4  65.6  ±  11.4  1.000  67.3  ±  12.8  1.000  0.681
HbA1c (%)  5.47  ±  1.12  5.36  ±  1.06  0.001  5.41  ±  1.10  0.232  0.003
TC (mg/dL) 192.4  ±  28.8 196.3  ±  29.7 0.662  197.2  ±  26.5  0.600  0.352
HDL-C, mg/dL 47.8  ±  12.5 47.5  ±  12.9 1.000  50.2  ±  13.7  0.184  0.051
Triglycerides (mg/dL) 146.6  ±  77.1 137.1  ±  70.7 0.399  134.4  ±  52.3 1.000  0.477
Creatinine (mg/dL) 0.83  ±  0.16 0.86  ±  0.17 0.374  0.86  ±  0.17 0.185  0.108
CRP (mg/L)  1.9  ±  2.6  2.0  ±  2.4  1.000  1.6  ±  1.8  0.346  0.766
Data are presented as the mean ± SD. CAVI, cardio-ankle vascular index; BMI, body mass index; BP, blood pressure; HbA1c, hemoglobin
A1c; TC, total cholesterol; HDL-C, high density lipoprotein cholesterol; CRP, C-reactive protein.
* p-Values for comparison between baseline and 1 month.
† p-Values for comparison between baseline and 12 months.
‡ p-Values for comparison across all three occasions.
Table  4  Correlations  between  changes  in  CAVI  after  CPAP  treatments  and  baseline  parameters.
CAVI1 CAVI12
B  SE  ˇ  p  B  SE  ˇ  p
Age  −0.007  0.007  −0.192  0.309  0.006  0.010  0.120  0.527
Male gender  0.325  0.245  0.285  0.199  −0.130  0.410  −0.071  0.755
BMI −0.008  0.016  −0.097  0.611  0.004  0.023  0.035  0.853
Smoker −0.026  0.150  −0.033  0.864  0.069  0.207  0.063  0.743
Hypertension  −0.073  0.149  −0.093  0.627  0.347  0.197  0.316  0.089
Diabetes mellitus  0.159  0.248  0.121  0.526  0.170  0.344  0.093  0.624
ESS −0.036  0.020  −0.325  0.079  −0.045  0.028  −0.291  0.118
Use of  statins  0.027  0.180  0.028  0.883  0.290  0.226  0.240  0.210
Use of  ACE-I/ARB  −0.235  0.153  −0.279  0.135  0.385  0.208  0.331  0.074
Use of  CCB  0.110  0.158  0.131  0.491  0.490  0.200  0.421  0.021
Use of  beta  blocker  −0.260  0.170  −0.278  0.137  0.318  0.238  0.245  0.192
Use of  anti-diabetes  −0.114  0.300  −0.072  0.706  −0.014  0.416  −0.006  0.973
Systolic BP  −0.008  0.004  −0.319  0.086  −0.003  0.006  −0.104  0.585
Diastolic BP  −0.006  0.008  −0.140  0.461  −0.011  0.011  −0.187  0.323
Heart rate  0.006  0.006  0.186  0.325  −0.007  0.008  −0.149  0.431
HbA1c −0.040 0.067  −0.112  0.556  0.042  0.094  0.085  0.654
TC −0.002  0.003  −0.110  0.564  0.001  0.004  0.039  0.838
HDL-C −0.008 0.006  −0.236  0.209  −0.007  0.008  −0.147  0.439
Triglycerides 0.001  0.001  0.216  0.251  0.002  0.001  0.212  0.260
Creatinine −0.536  0.473  −0.209  0.267  −0.168  0.669  −0.047  0.804
CRP 0.047  0.294  0.030  0.875  −0.009  0.408  −0.004  0.983
LF −0.001  0.001  −0.174  0.357  0.001  0.001  0.271  0.147
HF 0.001  0.001  0.021  0.913  0.001  0.001  0.193  0.307
LF/HF −0.012  0.022  −0.100  0.598  0.033  0.030  0.206  0.275
AHI −0.002  0.004  −0.076  0.691  0.004  0.005  0.151  0.425
Lowest SO2 0.018  0.011  0.303  0.104  −0.008  0.016  −0.098  0.607
Arousal index  0.002  0.004  0.104  0.586  0.004  0.005  0.157  0.407
SWS −0.007  0.012  −0.106  0.578  0.014  0.017  0.158  0.404
REM sleep  −0.024  0.013  −0.324  0.080  −0.023  0.019  −0.219  0.246
CAVI, cardio-ankle vascular index; CPAP, continuous positive airway pressure; BMI, body mass index; ESS, Epworth sleepiness scale; ACE-
I, angiotensin-converting enzyme inhibitors; ARB, angiotensin II receptor blockers; CCB, calcium-channel blocker; BP, blood pressure;
HbA1c, hemoglobin A1c; TC, total cholesterol; HDL-C, high-density lipoprotein cholesterol; CRP, C-reactive protein; LF, low frequency;
HF, high frequency; AHI, apnea—hypopnea index; SO2, oxyhemoglobin saturation; SWS, slow wave sleep; REM, rapid eye movement.
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Table  5  Correlation  between  changes  in  CAVI  after  CPAP  treatments  and  changes  in  other  parameters,  applied  CPAP  level,  and
nightly CPAP  usage.
CAVI1 CAVI12
B  SE  ˇ  p  B  SE  ˇ  p
BMI 0.130  0.171  0.142  0.454  −0.008  0.124  −0.012  0.949
Systolic BP 0.005  0.005  0.192  0.309  0.008  0.007  0.214  0.255
Diastolic BP 0.013  0.009  0.249  0.185  0.022  0.010  0.380  0.038
Heart rate −0.010  0.007  −0.235  0.212  −0.007  0.009  −0.142  0.454
HbA1c 0.851 0.536  0.287  0.124  1.934  0.503  0.588  0.001
TC 0.001  0.004  0.012  0.950  0.001  0.005  0.042  0.824
HDL-C −0.022  0.012  −0.328  0.077  −0.036  0.014  −0.437  0.016
Triglycerides  −0.001  0.002  −0.107  0.573  0.001  0.001  −0.053  0.780
Creatinine −0.405 0.655  −0.116  0.541  −1.048  1.001  −0.194  0.304
CRP −0.172  0.364  −0.089  0.640  −0.060  0.742  −0.015  0.937
LF 0.001  0.001  0.415  0.022  −0.001  0.001  −0.040  0.835
HF −0.001  0.001  −0.327  0.078  −0.001  0.001  −0.072  0.705
LF/HF 0.079  0.019  0.621  <0.001  0.013  0.033  0.072  0.705
AHI 0.001  0.004  0.045  0.812  −0.007  0.005  −0.229  0.224
Lowest SO2 −0.031  0.013  −0.424  0.020  0.022  0.019  0.214  0.256
Arousal index  −0.003  0.004  −0.142  0.454  −0.005  0.005  −0.184  0.330
Applied CPAP  level
during  the  ﬁrst  month
0.006  0.043  0.027  0.886  —  —  —  —
Applied CPAP  level
from  the  ﬁrst  to  the
last  month
—  —  —  —  0.089  0.135  0.123  0.517
Night CPAP  usage  during
the  ﬁrst  month
−0.154  0.048  −0.519  0.003  —  —  —  —
Night CPAP  usage  from
the  ﬁrst  to  the  last
month
—  —  —  —  −0.550  0.077  −0.805  <0.001
CAVI, cardio-ankle vascular index; CPAP, continuous positive airway pressure; BMI, body mass index; BP, blood pressure; HbA1c,
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Discussion
The  present  study  has  given  rise  to  several  novel  and
important  ﬁndings.  First,  short-term  CPAP  therapy  reduced
arterial  stiffness,  as  shown  by  the  association  of  a  reduction
in  CAVI  with  the  nightly  usage  of  CPAP  and  reduction  in  sym-
pathetic  activity  expressed  by  LF/HF  in  HRV.  Second,  after
that  initial  reduction,  CAVI  gradually  increased  to  12  months
of  CPAP  therapy.  However,  the  CAVI  at  12  months  after  CPAP
initiation  was  still  below  the  baseline  level,  although  the
reduction  of  CAVI  from  baseline  to  12  months  was  not  statis-
tically  signiﬁcant.  Third,  CAVI12 was  related  to  the  use  of
ACE-I/ARB,  change  in  the  blood  glucose  control,  and  change
in  the  CPAP  compliance  from  the  initial  1  month  to  the  last
1  month.
Several  studies  have  reported  that  arterial  stiffness  is
reduced  by  relatively  short-term  CPAP  therapy.  Although  the
length  of  the  follow-up  period  (from  1  to  4  months)  and  the
indices  of  arterial  stiffness  [carotid-femoral  (cf)  or  brachial-
ankle  (ba)  PWV  or  augmentation  index  or  pulse  wave  analysis
(PWA)]  varied,  all  of  them  essentially  showed  a  signiﬁcant
reduction  in  arterial  stiffness  after  the  attenuation  of  OSA
with  CPAP  [19—24]. More  recently,  we  reported  that  CAVI
was  reduced  by  1  month  of  CPAP  therapy  in  association  with
b
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rin cholesterol; CRP, C-reactive protein; LF, low frequency; HF,
ration.
 reduction  in  vascular  inﬂammation  and  CPAP  compliance
28].  In  the  present  study,  we  conﬁrmed  the  reduction  in
AVI  by  short-term  CPAP  therapy  in  a  different  sample  of
atients  with  moderate-to-severe  OSA.  We  speculate  that
he  reductions  in  CAVI  during  only  1  month  of  therapy  were
ssociated  with  improvements  in  functional  vascular  dam-
ge.  In  general,  increased  arterial  stiffness  reﬂects  not  only
he  degree  of  structural  vascular  damage  (i.e.  arterioscle-
osis),  but  also  the  degree  of  functional  vascular  damage,
hich  is  associated  with  endothelial  dysfunction  and  sympa-
hetic  nervous  system  overactivation  [31,32]. In  particular,
ndothelial  dysfunction  and  sympathetic  overactivation  may
ffect  muscular  arterial  stiffness.  Since  CAVI  reﬂects  the
tiffness  of  the  aorta,  femoral  arteries,  and  tibial  arter-
es,  arterial  stiffness,  as  assessed  by  CAVI,  includes  not  only
lastic  arterial  stiffness,  but  also  muscular  arterial  stiffness.
mprovements  in  endothelial  function  and  sympathetic  over-
ctivation  by  quite  short-term  CPAP  therapy  in  patients  with
SA  have  already  been  reported  [33,34].  In  addition,  it  has
een  reported  that  a  change  in  baPWV,  which  also  includes
oth  elastic  and  muscular  arterial  stiffness,  is  related  to
mprovements  in  autonomic  dysfunction  [23,24]. Indeed,  we
ound  an  independent  relationship  between  CAVI1 and  the
eduction  in  sympathetic  activity  expressed  by  LF/HF  in
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he  present  study.  Therefore,  it  has  been  suggested  that
he  alleviation  of  OSA  in  association  with  improvements  in
ndothelial  and  autonomic  functions  might  alter  functional
ascular  damage  despite  short-term  CPAP  therapy.
Furthermore,  the  results  of  the  present  study  and  pre-
ious  studies  conducted  by  our  group  and  others  remind
s  of  the  importance  of  good  compliance  in  CPAP  therapy.
hillips  et  al.  showed  that  the  arterial  stiffness  assessed
y  PWA  was  reduced  by  2  months  of  CPAP  therapy  and
hat  there  was  a  relationship  between  the  change  in
rterial  stiffness  as  assessed  by  PWA  and  CPAP  compli-
nce  [22]. In  addition,  we  recently  reported  a  reduction
n  CAVI  following  1  month  of  CPAP  therapy  and  there
as  a  relationship  between  the  change  in  CAVI  and  CPAP
ompliance  in  a  different  sample  of  moderate-to-severe
SA  patients  [28]. In  the  present  study,  we  demon-
trated  a  signiﬁcant  independent  correlation  between  the
hange  in  CAVI  during  1  month  and  CPAP  compliance  in  a
ultivariate  stepwise  regression  analysis.  Therefore,  the
resent  study  also  conﬁrmed  the  existence  of  a  relation-
hip  between  a  reduction  in  arterial  stiffness  as  measured
y  CAVI  following  short-term  CPAP  therapy  and  CPAP
ompliance.
In  contrast,  limited  data  regarding  the  long-term  effects
f  OSA  treatment  using  CPAP  on  arterial  stiffness  are  avail-
ble.  Saito  et  al.  recently  reported  that  OSA  treatment  with
PAP  decreased  baPWV  in  the  initial  6  months,  and  then  the
aPWV  gradually  increased  from  6  to  24  months  [35]. How-
ver,  the  baPWV  value  at  24  months  after  CPAP  initiation
as  still  below  the  baseline  level,  although  the  difference
etween  baseline  and  24  months  did  not  reach  statistical
igniﬁcance.  The  authors  of  that  article  speculated  that  the
ncrease  in  baPWV  from  6  to  24  months  was  due  to  nat-
ral  progression  associated  with  the  aging  process.  In  the
resent  study,  a  similar  change  in  CAVI  was  observed;  CAVI
igniﬁcantly  decreased  during  the  initial  month,  and  then
radually  increased  from  1  to  12  months.  However,  the  CAVI
t  12  months  was  still  below  the  baseline  value,  although
here  was  no  statistically  signiﬁcant  difference.  However,
ur  study  differs  from  the  study  by  Saito  et  al.  [35]  in  the
ollowing  ways:  (1)  CAVI  was  used  as  an  arterial  stiffness
arameter  and  (2)  the  follow-up  term  was  shorter  than  that
n  their  study.  Indeed,  Saito  et  al.  [35]  found  a  signiﬁcant
eduction  at  12  months  after  the  initiation  of  CPAP,  as  com-
ared  with  the  baseline,  but  this  was  not  seen  in  our  study.
ecause  BP  values  strongly  affect  baPWV  values  [36], and
ecause  the  white  coat  phenomenon  can  occur  frequently
n  patients  with  OSA  [37], baPWV  values  among  patients
ith  OSA  should  be  interpreted  with  caution.  From  this  per-
pective,  we  previously  reported  that  CAVI  values  showed  a
eaker  correlation  with  BP,  compared  to  baPWV,  and  that
he  reproducibility  of  CAVI  measures  was  quite  good  [27].
hus,  the  change  in  CAVI  might  reﬂect  a  change  in  arte-
ial  stiffness  independent  of  a  change  in  BP  and  a  change
n  CAVI  and  in  baPWV  may  be  slightly  different.  Actually,
aito  et  al.  [35]  found  that  changes  in  BP  were  signiﬁ-
antly  independently  correlated  with  both  short-term  and
ong-term  changes  in  baPWV.  However,  we  did  not  ﬁnd  a
igniﬁcant  independent  relationship  between  changes  in  BP
nd  CAVI12.  Instead,  in  the  present  study,  we  found  that
CAVI12 was  related  to  HbA1c,  use  of  ACE  or  ARB,  and
CPAP  usage.
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In terms  of  blood  glucose  control,  we  found  a  signiﬁcant
eduction  in  HbA1c  levels  1  month  after  the  initiation  of
PAP,  even  though  1  month  seems  to  be  too  fast  for  the
evels  of  HbA1c  to  reﬂect  a  change  in  glucose  metabolism.
lthough  the  reason  for  this  is  unknown,  it  has  been  reported
hat  an  attenuation  of  OSA  by  CPAP  can  improve  insulin  sen-
itivity  and  this  can  happen  in  the  short  term  (i.e.  within  1
onth)  [38]. These  changes  might  affect  the  observed  quick
hanges  in  HbA1c  levels.  We  also  found  signiﬁcant  reduction
n  LF/HF  just  1  night  after  CPAP  application  (i.e.  CPAP  titra-
ion)  in  the  present  study.  Such  reduction  in  sympathetic
ctivity  could  affect  the  reduction  in  insulin  sensitivity  [38]
nd  consequently  decrease  HbA1c  levels.  In  the  long  term
ollow-up,  such  reduction  in  HbA1c  levels  can  retard  the
evelopment  of  arterial  stiffness.  Therefore,  our  study  indi-
ates  that  maintaining  good  glucose  control  levels  after
PAP  initiation  might  be  important  for  preventing  the  devel-
pment  of  arterial  stiffness.
Another  interesting  ﬁnding  of  the  present  study  is  the
elationship  between  CAVI12 and  the  use  of  ACE-I/ARB.
e  found  that  patients  treated  with  ACE-I/ARB  exhibited
 greater  reduction  in  CAVI.  It  was  reported  that  this  type  of
rug  could  reduce  CAVI,  possibly  through  both  BP  reduction
nd  BP  independent  mechanisms  [39—41]. Thus,  a  reduction
n  sympathetic  overactivation  by  CPAP-mediated  attenua-
ion  of  OSA  and  blockade  of  the  renin—angiotensin  system  by
ynergistic  or  additive  action  of  ACE-I/ARB  caused  a  reduc-
ion  in  CAVI.  Although  we  could  not  speciﬁcally  assess  this
ecause  of  the  small  number  of  subjects  in  the  present  study,
t  will  be  very  interesting  to  examine  whether  such  an  inter-
ction  between  CPAP  therapy  and  the  use  of  ACE-I/ARB  is
elated  to  changes  in  CAVI.  This  should  be  assessed  in  a
uture  large-scale  study  that  includes  a  larger  number  of
ubjects.
CPAP  compliance  also  played  an  important  role  in  long-
erm  follow-up.  We  found  that  CPAP  usage  independently
ffected  CAVI12.  Poor  compliance  might  be  associated  with
nsufﬁcient  reduction  in  sympathetic  overactivation,  and
ubsequently  result  in  insufﬁcient  control  on  HbA1c  level
nd  BP.  Indeed,  we  found  a  slight  increase  in  systolic  and
iastolic  BP  and  HbA1c  level  from  the  1st  month  as  com-
ared  to  that  at  12  months  after  CPAP  initiation,  which  was
robably  associated  with  a  slight  reduction  in  CPAP  usage.
hese  changes  can  affect  the  gradual  increase  in  CAVI  from  1
o  12  months.  Another  factor  that  may  inﬂuence  CAVI  is  the
hange  in  smoking  status  after  the  initiation  of  CPAP  ther-
py.  We  assessed  the  relationship  between  baseline  smoking
tatus  and  change  in  CAVI  after  1  month  and  12  months.
here  was  no  signiﬁcant  relationship  between  these  com-
onents  and  the  baseline  smoking  status,  though  we  did
ot  assess  the  relationship  between  smoking  status  after
PAP  initiation  and  the  change  in  CAVI.  Since  recent  observa-
ions  suggested  that  smoking  signiﬁcantly  and  immediately
ffected  CAVI  [42,43],  the  increase  in  CAVI  from  1  month  to
2  months  might  be  inﬂuenced  by  alterations  of  smoking  sta-
us.  However,  we  did  not  obtain  data  about  smoking  status
uring  follow-up.  This  should  be  assessed  in  future  studies.tudy limitations
he  ﬁrst  limitation  is  the  small  number  of  subjects  and  the
eterogeneity  of  the  sample.  Only  30  patients,  including
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both  men  and  women,  those  with  and  without  hypertension,
and  those  with  and  without  diabetes  mellitus,  were  enrolled
in  the  present  study.  Since  the  number  of  subjects  in  our
study  was  relatively  small,  from  the  statistical  point  of  view,
we  should  take  into  account  the  possibilities  of  type  I  and
II  errors.  Second,  there  was  no  control  group  that  included
patients  with  OSA  but  who  did  not  receive  CPAP  therapy.
Therefore,  we  still  do  not  know  the  actual  natural  course
of  CAVI  in  patients  with  OSA.  A  future  study  in  which  both
OSA  patients  with  and  without  CPAP  therapy  are  enrolled  is
warranted  in  order  to  evaluate  the  effect  of  CPAP  therapy
for  OSA  on  CAVI.
Conclusion
We  found  a  signiﬁcant  reduction  in  CAVI  at  1  month  after
CPAP  therapy;  this  reduction  was  associated  with  CPAP  com-
pliance  and  reduction  in  sympathetic  activity.  The  CAVI
increased  during  the  subsequent  12  months.  However,  CAVI
at  12  months  after  CPAP  initiation  was  still  below  the  base-
line  level,  and  the  change  in  CAVI  during  long-term  CPAP
therapy  was  related  to  the  use  of  ACE-I/ARB,  blood  glucose
control,  and  change  in  CPAP  usage.  CPAP  therapy  for  OSA
might  immediately  improve  functional  vascular  damage,
possibly  through  an  improvement  in  endothelial  function
and  through  reduction  in  sympathetic  overactivation,  par-
ticularly  in  patients  with  good  compliance  to  CPAP.  On  the
other  hand,  the  control  of  blood  glucose  levels,  use  of  ACE-
I/ARB,  and  CPAP  compliance  might  affect  long-term  changes
in  CAVI.
Acknowledgment
This  study  was  partially  supported  by  the  Okinaka  Memorial
Foundation.
References
[1] Young T, Palta M, Dempsey J, Skatrud J, Weber S, Badr S. The
occurrence of sleep-disordered breathing among middle-aged
adults. N Engl J Med 1993;328:1230—5.
[2] Peker Y, Hedner J, Norum J, Kraiczi H, Carlson J. Increased
incidence of cardiovascular disease in middle-aged men with
obstructive sleep apnea: a 7-year follow-up. Am J Respir Crit
Care Med 2002;166:159—65.
[3] Punjabi NM, Caffo BS, Goodwin JL, Gottlieb DJ, Newman
AB, O’Connor GT, Rapoport DM, Redline S, Resnick HE, Rob-
bins JA, Shahar E, Unruh ML, Samet JM. Sleep-disordered
breathing and mortality: a prospective cohort study. PLoS Med
2009;6:e1000132.
[4] Redline S, Yenokyan G, Gottlieb DJ, Shahar E, O’Connor
GT, Resnick HE, Diener-West M, Sanders MH, Wolf PA, Ger-
aghty EM, Ali T, Lebowitz M, Punjabi NM. Obstructive sleep
apnea—hypopnea and incident stroke: the sleep heart health
study. Am J Respir Crit Care Med 2010;182:269—77.
[5] Gottlieb DJ, Yenokyan G, Newman AB, O’Connor GT, Punjabi
NM, Quan SF, Redline S, Resnick HE, Tong EK, Diener-West M,
Shahar E. Prospective study of obstructive sleep apnea and inci-
dent coronary heart disease and heart failure: the sleep heart
health study. Circulation 2010;122:352—60.
[6] Ishibashi Y, Osada N, Sekiduka H, Izumo M, Shimozato T, Hayashi
A, Kida K, Yoneyama K, Takahashi E, Suzuki K, Tamura M, Akashi
[81
YJ, Inoue K, Omiya K, Miyake F, et al. Peak time of acute coro-
nary syndrome in patients with sleep disordered breathing. J
Cardiol 2009;53:164—70.
[7] Koshino Y, Satoh M, Katayose Y, Kuroki K, Sekiguchi Y, Yamasaki
H, Yoshida K, Yasuda K, Tanigawa T, Kuga K, Aonuma K. Sleep
apnea and ventricular arrhythmias: clinical outcome, elec-
trophysiologic characteristics, and follow-up after catheter
ablation. J Cardiol 2010;55:211—6.
[8] Tamura A, Kawano Y, Ando S, Watanabe T, Kadota J. Association
between coronary spastic angina pectoris and obstructive sleep
apnea. J Cardiol 2010;56:240—4.
[9] Young T, Shahar E, Nieto FJ, Redline S, Newman AB, Gottlieb DJ,
Walsleben JA, Finn L, Enright P, Samet JM, Sleep Heart Health
Study Research Group. Predictors of sleep-disordered breath-
ing in community-dwelling adults: the Sleep Heart Health
Study. Arch Intern Med 2002;162:893—900.
10] Peppard PE, Young T, Palta M, Skatrud J. Prospective study of
the association between sleep-disordered breathing and hyper-
tension. N Engl J Med 2000;342:1378—84.
11] Punjabi NM, Polotsky VY. Disorders of glucose metabolism in
sleep apnea. J Appl Physiol 2005;99:1998—2007.
12] Somers VK, Dyken ME, Clary MP, Abboud FM. Sympathetic
neural mechanisms in obstructive sleep apnea. J Clin Invest
1995;96:1897—904.
13] Ryan S, Taylor CT, McNicholas WT. Systemic inﬂammation: a key
factor in the pathogenesis of cardiovascular complications in
obstructive sleep apnoea syndrome? Thorax 2009;64:631—6.
14] Lavie L. Obstructive sleep apnoea syndrome—–an oxidative
stress disorder. Sleep Med Rev 2003;7:35—51.
15] Drager LF, Bortolotto LA, Lorenzi MC, Figueiredo AC, Krieger
EM, Lorenzi-Filho G. Early signs of atherosclerosis in obstruc-
tive sleep apnea. Am J Respir Crit Care Med 2005;172:613—8.
16] Jelic S, Bartels MN, Mateika JH, Ngai P, DeMeersman RE, Basner
RC. Arterial stiffness increases during obstructive sleep apneas.
Sleep 2002;25:850—5.
17] Shiina K, Tomiyama H, Takata Y, Usui Y, Asano K, Hirayama Y,
Nakamura T, Yamashina A. Concurrent presence of metabolic
syndrome in obstructive sleep apnea syndrome exacerbates the
cardiovascular risk: a sleep clinic cohort study. Hypertens Res
2006;29:433—41.
18] Yim-Yeh S, Rahangdale S, Nguyen AT, Jordan AS, Novack
V, Veves A, Malhotra A. Obstructive sleep apnea and aging
effects on macrovascular and microcirculatory function. Sleep
2010;33:1177—83.
19] Kitahara Y, Hattori N, Yokoyama A, Nakajima M, Kohno N. Effect
of CPAP on brachial-ankle pulse wave velocity in patients with
OSAHS: an open-labelled study. Respir Med 2006;100:2160—9.
20] Drager LF, Bortolotto LA, Figueiredo AC, Krieger EM, Lorenzi GF.
Effects of continuous positive airway pressure on early signs of
atherosclerosis in obstructive sleep apnea. Am J Respir Crit
Care Med 2007;176:706—12.
21] Kohler M, Pepperell JC, Casadei B, Craig S, Crosthwaite N,
Stradling JR, Davies RJ. CPAP and measures of cardiovascular
risk in males with OSAS. Eur Respir J 2008;32:1488—96.
22] Phillips CL, Yee B, Yang Q, Villaneuva AT, Hedner J, Berend
N, Grunstein R. Effects of continuous positive airway pres-
sure treatment and withdrawal in patients with obstructive
sleep apnea on arterial stiffness and central BP. Chest
2008;134:94—100.
23] Shiina K, Tomiyama H, Takata Y, Yoshida M, Kato K, Saruhara
H, Hashimura Y, Matsumoto C, Asano K, Usui Y, Yamashina
A. Effects of CPAP therapy on the sympathovagal balance
and arterial stiffness in obstructive sleep apnea. Respir Med
2010;104:911—6.24] Kuramoto E, Kinami S, Ishida Y, Shiotani H, Nishimura Y. Contin-
uous positive nasal airway pressure decreases levels of serum
amyloid A and improves autonomic function in obstructive
sleep apnea syndrome. Int J Cardiol 2009;135:338—45.
8[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[2  
25] Yambe T, Yoshizawa M, Saijo Y, Yamaguchi T, Shibata M, Konno
S, Nitta S, Kuwayama T. Brachio-ankle pulse wave velocity
and cardio-ankle vascular index (CAVI). Biomed Pharmacother
2004;58(Suppl. 1):S95—8.
26] Shirai K, Utino J, Otsuka K, Takata M. A novel blood pressure-
independent arterial wall stiffness parameter; cardio-ankle
vascular index (CAVI). J Atheroscler Thromb 2006;13:101—7.
27] Kumagai T, Kasai T, Kato M, Naito R, Maeno K, Kasagi S, Kawana
F, Ishiwata S, Narui K. Establishment of the cardio-ankle vas-
cular index in patients with obstructive sleep apnea. Chest
2009;136:779—86.
28] Kasai T, Inoue K, Kumagai T, Kato M, Kawana F, Sagara M, Ishi-
wata S, Ohno M, Yamaguchi T, Momomura S, Narui K. Plasma
pentraxin3 and arterial stiffness in men with obstructive sleep
apnea. Am J Hypertens 2011;24:401—7.
29] Sleep-related breathing disorders in adults: recommendations
for syndrome deﬁnition and measurement techniques in clin-
ical research. The Report of an American Academy of Sleep
Medicine Task Force. Sleep 1999;22:667—89.
30] Johns MW. A new method for measuring daytime sleepiness:
the Epworth sleepiness scale. Sleep 1991;14:540—5.
31] Safar ME, Levy BI, Struijker-Boudier H. Current perspectives
on arterial stiffness and pulse pressure in hypertension and
cardiovascular diseases. Circulation 2003;107:2864—9.
32] Zieman SJ, Melenovsky V, Kass DA. Mechanisms, pathophysiol-
ogy, and therapy of arterial stiffness. Arterioscler Thromb Vasc
Biol 2005;25:932—43.
33] Ip MS, Tse HF, Lam B, Tsang KW, Lam WK. Endothelial function
in obstructive sleep apnea and response to treatment. Am J
Respir Crit Care Med 2004;169:348—53.
34] Narkiewicz K, Kato M, Phillips BG, Pesek CA, Davison DE, Somers
VK. Nocturnal continuous positive airway pressure decreases
daytime sympathetic trafﬁc in obstructive sleep apnea. Circu-
lation 1999;100:2332—5.
35] Saito T, Saito T, Sugiyama S, Asai K, Yasutake M, Mizuno K.
Effects of long-term treatment for obstructive sleep apnea on
pulse wave velocity. Hypertens Res 2010;33:844—9.
[M.  Kato  et  al.
36] Tomiyama H, Yamashina A, Arai T, Hirose K, Koji Y, Chikamori
T, Hori S, Yamamoto Y, Doba N, Hinohara S. Inﬂuences of age
and gender on results of noninvasive brachial-ankle pulse wave
velocity measurement—–a survey of 12517 subjects. Atheroscle-
rosis 2003;166:303—9.
37] Garcia-Rio F, Pino JM, Alonso A, Arias MA, Martinez I,
Alvaro D, Villamor J. White coat hypertension in patients
with obstructive sleep apnea—hypopnea syndrome. Chest
2004;125:817—22.
38] Lam JC, Lam B, Yao TJ, Lai AY, Ooi CG, Tam S, Lam KS, Ip MS. A
randomised controlled trial of nasal continuous positive airway
pressure on insulin sensitivity in obstructive sleep apnoea. Eur
Respir J 2010;35:138—45.
39] Miyashita Y, Saiki A, Endo K, Ban N, Yamaguchi T, Kawana H,
Nagayama D, Ohira M, Oyama T, Shirai K. Effects of olmesartan,
an angiotensin II receptor blocker, and amlodipine, a calcium
channel blocker, on Cardio-Ankle Vascular Index (CAVI) in type
2 diabetic patients with hypertension. J Atheroscler Thromb
2009;16:621—6.
40] Bokuda K, Ichihara A, Sakoda M, Mito A, Kinouchi K,
Itoh H. Blood pressure-independent effect of candesar-
tan on cardio-ankle vascular index in hypertensive patients
with metabolic syndrome. Vasc Health Risk Manage 2010;6:
571—8.
41] Miyoshi T, Doi M, Hirohata S, Kamikawa S, Usui S, Ogawa H,
Sakane K, Izumi R, Ninomiya Y, Kusachi S. Olmesartan reduces
arterial stiffness and serum adipocyte fatty acid-binding pro-
tein in hypertensive patients. Heart Vessels 2010 November 10
[Epub ahead of print].
42] Noike H, Nakamura K, Sugiyama Y, Iizuka T, Shimizu
K, Takahashi M, Hirano K, Suzuki M, Mikamo H, Nak-
agami T, Shirai K. Changes in cardio-ankle vascular index
in smoking cessation. J Atheroscler Thromb 2010;17:
517—25.
43] Kubozono T, Miyata M, Ueyama K, Hamasaki S, Kusano K, Kubo-
zono O, Tei C. Acute and chronic effects of smoking on arterial
stiffness. Circ J 2011;75:698—702.
